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Abstract The renin–angiotensin–aldosterone system
plays an important role in the pathophysiology of hyper-
tension and is closely related with cardio- and cere-
brovascular events and chronic kidney diseases. Each
angiotensin receptor blocker (ARB) is important in the
treatment of hypertension, according to the results of recent
years. This is a practical review of the available evidence
on the different benefits of ARBs beyond their blood
pressure-lowering effect, with an emphasis on the differ-
ences found between the particular compounds and the
therapeutic implications of the findings, with specific ref-
erence to the co-morbidities.
Abbreviations
ACEI Angiotensin converting enzyme
inhibitor
ACTIVE-I Atrial Fibrillation Clopidogrel Trial




AMADEO A comparison of telMisartan versus
losArtan in hypertensive type 2 DiabEtic
patients with Overt nephropathy
ARB Angiotensin receptor blocker
AT2 Angiotensin II Type 2
ATHLETE ARB trial of hypertension in obese
patients with hyperinsulinemia assessed
by oral glucose tolerance test
CALM Candesartan And Lisinopril
Microalbuminuria study
CHARM Candesartan in Heart Failure-
Assessment of Reduction in Mortality
and Morbidity
CKD Chronic kidney disease
CV Cardiovascular
CVD Cardiovascular disease




ELITE Evaluation of Losartan In The Elderly
eNOS Endothelial Nitric Oxide Synthase
ESRD End-stage renal disease







HOMA-IR Homeostasis model assessment of
insulin resistance
IDNT Irbesartan Diabetic Nephropathy Trial
INNOVATION The INcipieNt to OVert: Angiotensin II
receptor blocker, Telmisartan,
Investigation On type 2
diabetic Nephropathy
IR Insulin resistance
K-MetS The Efficacy of Fimasartan for
Cardiovascular Events and Metabolic
Syndrome
LIFE Losartan Intervention For Endpoint
reduction
& Csaba Andra´s De´zsi
dcsa62@gmail.com
1 Department of Cardiology, Petz Alada´r County Teaching
Hospital, Gyor, Hungary
Am J Cardiovasc Drugs (2016) 16:255–266
DOI 10.1007/s40256-016-0165-4
MARVAL MicroAlbuminuria Reduction With
VALsartan
MI Myocardial infarction
MMSE Mini-Mental State Examination
MOSES The MOrbidity and Mortality after
Stroke-Eprosartan compared with
nitrendipine in Secondary prevention
study
mRNA Messenger Ribonucleic Acid
nNOS Neuronal Nitric Oxide Synthase
NYHA New York Heart Association
NYHA-FC New York Heart Association Functional
Classification
ONTARGET Ongoing Telmisartan Alone and in
Combination With Ramipril Global
End Point Trial
ORIENT Olmesartan Reducing Incidence of End
Stage Renal Disease in Diabetic
Nephropathy Trial




PRoFESS The Prevention Regimen for Effectively
Avoiding Second Strokes
RAAS Renin–angiotensin–aldosterone system
RENAAL Reduction of Endpoints in NIDDM with
the Angiotensin II Antagonist Losartan
Study
RESOLVD Randomized Evaluation of Strategies for
Left Ventricular Dysfunction
ROADMAP Randomized Olmesartan and Diabetes
Microalbuminuria Prevention Study
RR Relative Risk
Safe-KanArb Safety and Efficacy of Fimasartan in
Patients with Arterial Hypertension
SARTAN-AD A randomized, open label, proof of
concept study of Telmisartan vs.
Perindopril in hypertensive mild-
moderate Alzheimer’s disease patients
SCOPE Study on Cognition and Prognosis in the
Elderly
SPECT Single-photon emission computed
tomography
SUA Serum uric acid
TGF-b Transforming Growth Factor Beta
TRANSCEND Telmisartan Randomized Assessment
Study in ACE-Intolerant Subjects With
Cardiovascular Disease Trial
Val-HeFT Valsartan Heart Failure Trial
VALIANT VALsartan In Acute myocardial
iNfarcTion
VALUE The Valsartan Antihypertensive Long-
term Use Evaluation
VF-HT-AF Valsartan and Fluvastatin on
Hypertensive patients with
non-permanent Atrial Fibrillation
VIVALDI study to inVestIgate the efficacy of
telmIsartan versus VALsartan in
hypertensive type 2 DIabetic patients
with overt nephropathy
URAT Renal uric acid transporter
Key Points
Therapy customized for individuals is extremely
important, especially for patients with high blood
pressure who are increased risk of end organ
damage.
When initiating angiotensin receptor blocker
treatment, it is recommended to assess the clinical
effects, which are proven to be divergent today, of
each agent and their indications in light of the
comorbidities.
1 Introduction
The appearance of angiotensin receptor blockers (ARBs)
amongst the therapeutic options in the treatment of car-
diovascular diseases (CVDs) was a new milestone in the
history of hypertension treatment. It further widened the
range of possibilities for personalized therapy, especially
for patients who cannot tolerate the use of angiotensin
converting enzyme inhibitors (ACEIs). ARBs have shown
excellent efficacy, they have no negative metabolic effects
and they cause no accumulation of bradykinin. They also
have an ability to activate the angiotensin II type 2 (AT2)
receptors, which causes vasodilatation in the small vessels
and presumably leads to additional cardiac and renal
protection.
There is a vast amount of literature on antihypertensive
and cardiovascular (CV) therapeutic choices, and recom-
mendations are available as to when a renin-angiotensin-
aldosterone system (RAAS) inhibitor should be the first
drug of choice. According to the latest international
guidelines, ACEIs or ARBs should be preferred in patients
with co-morbid microalbuminuria, renal dysfunction and
chronic kidney disease (CKD), metabolic syndrome and
diabetes mellitus (DM), atherosclerosis, chronic
stable angina and previous myocardial infarction (MI),
atrial fibrillation (AF) as well as heart failure (HF) [1–3].
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As to which particular ARB should be preferred in case
of different co-morbid conditions, no guidance is available.
Also, there is a lack of substantial direct comparative trials
between different ARBs regarding their effects beyond
blood pressure lowering. Nevertheless, several studies are
available where certain ARBs have shown additional
beneficial effect; the present review of the available evi-
dence should provide help in treatment selection for indi-
vidual patients.
A comprehensive PubMed search was performed in
August 2015, using the key words ‘‘angiotensin receptor
blocker,’’ ‘‘azilsartan,’’ ‘‘candesartan,’’ ‘‘eprosartan,’’
‘‘irbesartan,’’ ‘‘losartan,’’ ‘‘olmesartan,’’ ‘‘telmisartan,’’
‘‘valsartan’’ and ‘‘fimasartan,’’ identifying relevant articles
concerning the efficacy of ARBs in clinical conditions
beyond hypertension. References of identified articles were
also searched for relevant articles (Tables 1, 2).
2 Prevention of Cardiovascular Events
and Mortality
CVDs account for about 30 % of all deaths in the world,
ischemic heart diseases and stroke being responsible for the
majority (4/5) of them. Underlying atherosclerosis can be
found in around 75 % of death cases due to CVDs [4].
The selective inhibition of angiotensin II on AT1
receptors blocks the systemic effects of the RAAS,
including vasoconstriction, stimulation of aldosterone
synthesis and renal absorption of sodium. Furthermore,
AT1 inhibition reduces cardiac and vascular oxidative
stress, inflammation and remodeling, thus improving
endothelial dysfunction. The decrease of RAAS-related
vascular inflammation may prevent the development of
atherosclerosis, consequently reducing the risk of major
CV events [4–6].
The blockade of AT1 receptors also results in increased
angiotensin II activity on AT2 receptors, leading to
vasodilation and natriuresis through bradykinin, nitric
oxide, prostaglandin and cyclic guanosine monophosphate
(GMP) pathways, generally showing an opposite effect to
the action of AT1 receptors. Thus selective blockade of
AT1 receptors can contribute to additional CV protection of
ARBs [4, 7].
The primary goal of today’s therapeutic strategy for
CVDs is to control and decrease the existing risk factors
and consequently decrease the occurrence of CV events
and consequent morbidity and mortality. The designs of
several recent clinical trials reflect this approach, investi-
gating the reduction of CV events as trial endpoints. ARBs
have shown the ability to reduce the risk of stroke and HF
as well as the risk of major CV events in prospective
randomized trials [8].
2.1 Cardiovascular Protection
Telmisartan is the only ARB indicated for the reduction of
CV morbidity in patients with manifest atherothrombotic
CVD, based on the results of the ONTARGET study [9]. It
has shown a similar reduction in the composite endpoint of
CV death, MI, stroke, or hospitalization due to HF to that
of the active comparator ramipril [10]. The TRANSCEND
study, while it failed to reach the composite primary end-
point, showed that telmisartan did reduce hospitalizations
for CV reasons, and left ventricular hypertrophy, and fewer
patients had the combination of macrovascular and
microvascular events plus microalbuminuria [11]. In
addition, a combined analysis with data from PRoFESS
showed a significant benefit of telmisartan on CV death as
well as MI and stroke [12].
Losartan has also shown benefits in reducing the relative
risk of the composite endpoint of death, MI or stroke by
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13 % compared with atenolol in the LIFE study, with more
benefit amongst diabetic patients, where mortality was
reduced by 39 % [13].
2.2 Heart Failure
Valsartan, candesartan and losartan are indicated for the
second-line treatment of HF in cases of ACEI intolerance
[9].
In HF patients not receiving ACEIs, valsartan reduced
all-cause mortality by 33 % and composite mortality and
morbidity risk by 44 % compared with placebo in the Val-
HeFT trial. In the overall study population, valsartan
caused significant improvements in New York heart
association (NYHA) class, ejection fraction, and HF signs
and symptoms and reduced the rate of hospitalization
[14].
Candesartan had an effect similar to that of enalapril on
left ventricular function and New York heart association
functional classification (NYHA-FC) in the RESOLVD
study [15]. The consequent CHARM trial showed that
candesartan also caused a significant reduction in the risk
of CV deaths and hospital admissions for HF compared
with placebo [16].
The ELITE I and II trials have both shown that in
elderly HF patients, treatment with losartan was similar to
that with captopril in terms of all-cause mortality, sudden
death or resuscitated arrests as well as NYHA class
improvement. In the first ELITE study, there was also a
lower mortality found with losartan, primarily due to a
greater reduction in sudden cardiac death [17, 18]. It seems
that the use of 150 mg losartan has additional benefits to
those of the 50-mg dose, as it reduced the rate of death or
admission for HF and left ventricular ejection fraction [19].
Table 2 Summary conclusions
When? Which one to give? Which one to avoid?
Clinical condition of concern First ARBs of choice ARBs with potentially beneficial effects ARBs with potentially negative effect
Cardiovascular prevention Telmisartan [10–12] Losartan [13]
Heart failure Valsartan [14]
Candesartan [15, 16]
Losartan [17–19]
Myocardial infarction Valsartan [20, 21] Telmisartan [10, 22]
Stroke Losartan [23] Telmisartan [24, 25]
Candesartan [27]
Eprosartan [28]
Atrial fibrillation Telmisartan [34–36] Losartan [29, 33]
Candesartan [30]
Valsartan [31, 32]
Diabetes mellitus Telmisartan [47, 50, 54, 55]











Metabolic syndrome Telmisartan [72, 75, 77–79] Valsartan [81, 82]
Hyperuricemia Losartan [89–91] Irbesartan [93] Candesartan [89–91]
Erectile dysfunction Valsartan [101–104]
Losartan [105, 106]
Irbesartan [106, 108]
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2.3 Myocardial Infarction
Valsartan is also indicated for the treatment of patients with
HF or asymptomatic left ventricular systolic dysfunction
after a recent MI [9]. Treatment with valsartan resulted in
similar changes in cardiac volume, ejection fraction, and
infarct segment length between baseline and 20 months
after MI compared with ramipril in the VALIANT trial.
Valsartan was non-inferior to captopril in terms of total
mortality and CV death, MI and HF [20]. Valsartan also
showed long-term benefits when administered prior to
percutaneous coronary intervention, resulting in a signifi-
cantly reduced ratio of major adverse CV events [21].
The use of telmisartan was associated with a significant
reduction in the number of MIs in hypertensive patients
during the TRANSCEND trial compared with normoten-
sive individuals [22].
In comparison with ramipril, telmisartan use resulted in
a similar incidence of MI in patients with vascular disease
of high-risk diabetes [10].
2.4 Stroke
Losartan is also indicated for hypertensive patients at risk
of stroke [9]. In the LIFE study, losartan reduced the risk of
any stroke, fatal stroke and atherothrombotic stroke sig-
nificantly more than did atenolol (by 40, 70 and 45 %,
respectively) [23].
Telmisartan showed a nonsignificant reduction of
recurrent stroke versus placebo in the PRoFESS trial;
according to a post hoc analysis, from 6 months, the
reduction of the number of strokes was significant [24, 25].
In elderly patients with isolated systolic hypertension,
candesartan treatment resulted in a significant relative risk
reduction of all stroke events in comparison with other
antihypertensive treatment [26]. Candesartan also showed
beneficial effects used as a 7-day course following an acute
ischemic stroke, significantly improving CV morbidity and
mortality [27].
The MOSES trial, investigating high-risk hypertensive
stroke patients, showed that compared to nitrendipine,
eprosartan therapy resulted in significantly fewer cere-
brovascular events during the 2.5 years of follow-up [28].
2.5 Atrial Fibrillation
The use of losartan, valsartan and candesartan has been
associated with a reduced incidence of new-onset AF,
according to post hoc analyses of the LIFE, VALUE,
CHARM and Val-HeFT trials, with a relative risk reduc-
tion of 20–35 % in new-onset cases [29–32]. Losartan was
also found to suppress the maximum duration and the total
duration of paroxysmal AF in patients with sick sinus
syndrome without causing any significant hemodynamic
changes [33].
Telmisartan significantly reduced the recurrence of AF
compared with carvedilol, amlodipine as well as ramipril
[34–36].
Studies with recurrent AF with other ARBs are slightly
conflicting. Fogari et al. [37, 38] have found both valsartan
and losartan to prevent new occurrences of AF compared
with amlodipine. However, the GISSI-AF Investigators
could not confirm the preventive role of valsartan in patients
who already had AF in their history [39, 40]. Similarly,
although irbesartan showed a significant reduction of
recurrent AF in the study by Madrid et al. [41] in patients
with persistent AF, there was no difference regarding
recurrent AF between irbesartan and placebo in the
ACTIVE-I trial; irbesartan reduced neither the risk of hos-
pitalization for AF nor the risk of cardioversion [41, 42].
In the case of valsartan, the VF-HT-AF study has been
designed and will probably shed more light on the benefits
of this drug in the upstream therapy of recurrent AF in
hypertensive patients [43].
3 Prevention of Diabetes Mellitus and Associated
Risk Factors
The occurrence of hypertension is twice as common in
diabetic patients as in the non-diabetic population. DM is a
general CV risk factor; it causes elevated susceptibility to
atherosclerosis, and it is an independent predictor of
numerous adverse outcomes, including HF, stroke and
peripheral vascular disease. Adequate glycemic as well as
blood pressure control are therefore essential in the treat-
ment of diabetic patients and those at risk of DM [4].
RAAS inhibitors have been found to improve insulin
sensitivity. The anti-diabetic properties of ARBs may also
include activation of Peroxisome proliferator-activated
receptor gamma (PPAR-c), augmentation of blood flow to
muscles and upregulation of glucose transporter expression
in muscle, suppression of oxidative stress and anti-in-
flammatory action, inhibition of fibrosis through inhibition
of transforming growth factor beta (TGF-b) as well as
enhancement and modulation of insulin signaling [44–47].
The novel compound azilsartan has also shown insulin-
sensitizing effects in obese rats, and clinical trials are on
their way to assess the effect on human insulin resistance
(IR) [48, 49].
According to a meta-analysis of eight trials, telmisartan
was superior to other ARBs in reducing fasting plasma
glucose and increasing adiponectin levels. Using an 80-mg
dose, telmisartan may also reduce fasting plasma insulin
levels as well as homeostasis model assessment of insulin
resistance (HOMA-IR) [50].
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ARB therapy can reduce the incidence of new onset
diabetes compared with placebo in patients with high CV
risk and/or hypertension [51, 52]. The meta-analysis of
LIFE, SCOPE and VALUE trials has shown that losartan,
candesartan as well as valsartan can cause a clinically
significant decrease in the incidence of new onset diabetes,
with a combined estimated relative risk (RR) of 0.80 for all
the three agents [53]. Similarly, the meta-analysis of the
TRANSCEND and PRoFESS trials has shown that treat-
ment with telmisartan is associated with a 16 % reduction
in the risk of new onset DM compared with placebo [54].
These results are also supported by a population-based
cohort of hypertensive patients, showing a similar protec-
tive effect for valsartan, irbesartan, candesartan and
telmisartan, using losartan as a baseline reference; mean-
while, olmesartan use resulted in a slightly increased haz-
ard ratio [47].
ARBs have also shown cardioprotective properties in
patients with type 2 DM. In a population-based cohort
study among older diabetic patients, telmisartan and val-
sartan (with an adjusted hazard ratio of 0.85 and 0.86,
respectively) were both associated with a lower risk of
admission to hospital for acute MI, stroke or HF, compared
with irbesartan. With respect to the same primary outcome,
no differences were found between irbesartan, losartan or
candesartan [55].
4 Renal End-Organ Protection
In patients with CKD, hemodynamic changes occur during
the adaptation to functional tissue loss, regardless of the
etiology of the renal failure. Stimulation of the RAAS
increases intraglomerular pressure, leading to capillary
damage, increased proteinuria and consequent interstitial
inflammation and fibrosis. Proteinuria is an independent
risk factor for end-stage renal disease (ESRD) and mor-
tality; its reduction is associated with a decreased rate of
glomerular filtration rate decline. Therefore both blood
pressure control and reduction of proteinuria play a key
role in CKD management in hypertensive patients with or
without DM [56, 57].
According to a recent network meta-analysis, ARBs are
the most effective antihypertensive agents for the preven-
tion of ESRD, showing significant benefit compared with
placebo [58]. In diabetic patients with nephropathy,
administration of ARBs suppresses both oxidative stress
and inflammation, patients with higher renal stress marker
values benefiting the most in terms of oxidative stress
marker and urinary albumin excretion rate reduction [59].
Compared with placebo, losartan given in addition to
conventional antihypertensive treatment reduced the risk of
ESRD by 28 % and decreased the level of urinary protein
excretion by 35 % in patients with coexistent diabetic
nephropathy in the RENAAL study [60].
In the IDNT trial, irbesartan reduced the risk of doubling
serum creatinine levels by 33 % and the onset of ESRD by
23 % compared with placebo in hypertensive patients with
nephropathy due to DM. Benefits of irbesartan use com-
pared with amlodipine treatment were even more pro-
nounced [61]. Higher doses of irbesartan also caused a
sustained long-term reduction in urinary albumin excretion
rate, even after withdrawal of all antihypertensive treat-
ment [62].
A recent meta-analysis of 20 randomized controlled
telmisartan trials (ONTARGET, TRANSCEND, DETAIL,
INNOVATION, AMADEO and VIVALDI, among others)
performed mainly in diabetic patients concluded that
telmisartan therapy is likely effective in the improvement
of proteinuria or in the prevention of its progression.
Telmisartan caused a statistically significant reduction in
percent changes of urinary albumin/protein excretion and
urinary albumin/protein to creatinine ratio with telmisartan
relative to other ARBs, ACEIs and other therapy by 20, 14
and 40 %, respectively [63].
The addition of valsartan to conventional therapy sig-
nificantly slowed the rate of renal function decline, reduced
the doubling of serum creatinine levels and delayed the
appearance of ESRD in hypertensive patients with advanced
CKD compared with placebo [64]. In patients with type II
diabetes and microalbuminuria with or without hyperten-
sion, valsartan significantly reduced elevated urine albumin
excretion compared with baseline in the MARVAL trial.
Valsartan also induced regression to normoalbuminuria in a
significantly greater proportion of patients than amlodipine
(29.9 vs. 15.5 %) [65]. Valsartan reduced albuminuria by
more than 50 in 37.6 % and returned to normal in 18.9 % of
the assessed hypertensive patients in an open-label obser-
vational study, with a more pronounced effect on those with
DM than on the non-diabetic population [66].
Candesartan was shown to reduce urinary albumin/cre-
atinine ratio by 30 % in the CALM study [67].
Olmesartan was shown to increase the time to the onset
of microalbuminuria in diabetic patients in the ROADMAP
study. However, a higher rate of death from CV causes was
observed in the olmesartan group than in the placebo group
among patients with preexisting coronary heart disease
[68]. CV death was also higher in the olmesartan group in
the ORIENT trial investigating diabetic patients with overt
nephropathy [69]. A retrospective cohort analysis of DM
patients has also found that olmesartan use was associated
with an adjusted hazard for all-cause hospitalization or all-
cause mortality of 1.11 in subjects with a history of CVD
and 1.21 in subjects with CKD [70]. The increase found in
the risk of fatal CV events might be attributable to the
aggressive blood pressure lowering properties of
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olmesartan, or otherwise, the result of the so-called J-curve
phenomenon [71].
5 Obesity and Metabolic Syndrome
Abdominal obesity is often associated with hypertension.
Obese patients with hypertension are also more prone to
developing diabetes than those who are normotensive. The
severity of diseases related to obesity (such as DM or
CVD) primarily correlates to body fat distribution. The
negative relationship between adiponectin and adipose
tissue is stronger with visceral fat rather than subcutaneous
fat; visceral fat remodeling therefore can be beneficial in
metabolic syndrome [72]. Hypoadiponectinemia is a key
factor in metabolic syndrome. Adiponectin levels can be
increased by insulin sensitizers and PPAR-c agonists, as
PPAR-c may ameliorate the accumulation of visceral adi-
pose tissues and sensitize insulin action [73].
One of the important features of drugs that suppress the
RAAS is the absence of negative metabolic effects. Among
antihypertensive drugs, thiazide diuretics and b-blockers
enhance IR. Dihydropyridine calcium antagonists have no
apparent effects on glucose metabolism and IR, while
ACEIs and ARBs can enhance insulin sensitivity [74].
The PPAR-c agonist telmisartan improves both hemo-
dynamic and metabolic abnormalities found in hyperten-
sive patients with obesity. The results of a recent meta-
analysis showed that telmisartan therapy significantly
improves metabolic parameters such as fasting glucose,
insulin, hemoglobin A1c: glycosylated hemoglobin
(HbA1c) levels and HOMA index in patients with meta-
bolic syndrome. Data for adiponectin levels were less
robust but nevertheless showed significant improvement
[75]. The ATHLETE study also showed that in obese
patients with hypertension and IR, telmisartan significantly
improved the hyperinsulin response to glucose loading
[76]. Telmisartan treatment was further associated with
improvement of vascular inflammation, reductions in vis-
ceral fat and serum TNF-a levels as well as increases in
serum adiponectin in a number of studies [72, 77–79].
When compared with telmisartan, eprosartan, losartan or
valsartan did not show the above detailed beneficial effects
in obese hypertensive subjects [72, 78, 80]. However, in
obese but otherwise healthy subjects, valsartan did
decrease fasting plasma insulin levels, and in patients with
impaired glucose metabolism, valsartan treatment reduced
abdominal subcutaneous adipocyte size as well as adipose
tissue macrophage infiltration markers, and increased
fasting and postprandial adipose tissue blood flow com-
pared with placebo [81, 82].
Although it has not yet been supported by clinical evi-
dence, fimasartan, the ninth ARB, may also be mentioned
here. It was found to have a successful antihypertensive
efficacy and safety profile in Safe-KanArb [83], which is a
large cross-sectional population study in South Korea.
Furthermore, the same results were observed in a recent
study conducted on a low-to-moderate risk hypertension
population in Mexico [84]. Currently, treating high blood
pressure is the sole indication for it use in the aforemen-
tioned countries. However, the results of the K-MetS study
[85], which are expected to be released in 2016, aside from
providing information on the antihypertensive efficacy of
fimasartan-based treatment, are going to provide valuable
information concerning other potential effects detected in
patients with metabolic syndrome in case of such
treatments.
6 Hyperuricemia
Several observations indicate that hyperuricemia is an
independent risk factor for CVD. Raised serum uric acid
(SUA) levels are found in approximately 25 % of hyper-
tensive patients; SUA may further be increased by the use
of loop and thiazide diuretics [86, 87]. The renal uric acid
transporter (URAT1) was shown to be involved in the
effect of ARBs on SUA level. Losartan and pratosartan
have been found to be potent inhibitors of URAT1. How-
ever, there is a lack of inhibitory effect of candesartan,
olmesartan and valsartan on URAT1, whereas a trans-
stimulation of URAT1 by these ARBs was found at higher
concentrations. Such trans-stimulatory effects may lead to
an increase of SUA level [88].
Telmisartan exhibited only a cis-inhibitory effect but not a
trans-stimulatory effect on URAT1. However, urinary excre-
tion of telmisartan is less than 0.02 %; therefore no uricosuric
effect of telmisartan can be observed clinically [88].
Losartan increased the excretion of uric acid and
decreased the SUA level in both healthy and hypertensive
subjects. Candesartan, however, was found to slightly but
significantly increase uric acid levels [89–91]. Eprosartan
had no effect on SUA concentrations or urine uric acid
excretion in patients with mild-to-moderate essential
hypertension [92]. Lately, irbesartan treatment was also
found to be associated with the decrease of SUA levels, but
only in patients with higher baseline SUA values [93].
7 Erectile Dysfunction
Erectile dysfunction (ED) seems to be strongly correlated
with hypertension, and is also considered an early predictor
of silent coronary heart disease. ED was found to be a
potent predictor of all-cause death and the composite of CV
death, MI, stroke and HF in men with CVD in the
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ONTARGET/TRANSCEND trials. Also, older CV drugs
such as b-blockers or some diuretics seem to have a
deteriorating effect on erectile function [94, 95]. Penile
cavernous smooth muscle tone is partially balanced by
bradykinin-induced relaxation and angiotensin II-induced
contraction. Since the tissue and plasma levels of both
peptides are regulated by the RAAS system, its inhibitors
would be a prudent choice in the treatment of hypertension
in patients with ED [96].
Several preclinical and clinical studies have shown
beneficial effects of some ARBs on sexual function;
however, not all studies have shown significant results
compared with placebo [97, 98]. In mice, irbesartan was
shown to improve penile endothelial function by reduction
of vascular and cavernosal oxidative stress, while olme-
sartan improved the malondialdehyde concentrations and
increased messenger ribonucleic acid (mRNA) levels of
endothelial nitric oxide synthase (eNOS) and neuronal
nitric oxide synthase (nNOS) in the penis [99, 100].
In large prospective studies, the use of valsartan
increased the rate of sexual intercourses per week and
caused a reduction in ED, with improved orgasmic func-
tion, intercourse and overall sexual satisfaction in hyper-
tensive men [101, 102]. In comparative studies, long-term
use of valsartan was also shown to significantly improve
sexual activity in comparison with the b-blockers carve-
dilol and atenolol, with the latter also reducing serum
testosterone levels [103, 104].
Treatment with losartan improved erectile function,
sexual satisfaction and frequency of sexual activity in
hypertensive patients. Losartan alone or in combination
with tadalafil significantly improved ED in diabetic
patients, those with mild to moderate ED profiting the most
from its use [105, 106].
In hypertensive patients with the metabolic syndrome,
treatment with irbesartan alone or in combination with
hydrochlorothiazide was associated with an improvement
of sexual desire, frequency of sexual contacts and erectile
function. Irbesartan also improved erectile function
recovery in prostatectomized patients [107, 108].
Treatment with telmisartan did not significantly improve
or worsen ED in the ONTARGET/TRANSCEND studies
[94].
8 The Future of Angiotensin Receptor Blockers:
Protection of Cognitive Function
The human brain is extremely dependent on proper func-
tioning of its vascular system. There is ample evidence
supporting the causal relationship of vascular dysfunction
and hypertension with the development of dementia and
the decline of cognitive function [109–113]. Furthermore,
hypertension also seems to increase the risk and progres-
sion of Alzheimer’s disease (AD) [114, 115].
According to the so-called AT2 hypothesis, parallel to
the selective blockade of AT1 receptors during ARB use,
AT2 is activated and contributes to some protective effects
of ARBs. These protective qualities distinguish them from
ACEIs, for which such modulator effects are not present. In
the brain, the activation of AT2 decreases inflammation,
superoxide production and axon degeneration, promotes
neuronal cell differentiation and leads to activation of the
repair systems [116].
Several animal studies have shown the benefits of ARBs
on cognitive function. In adult and also aged mice, losartan
exhibited protection against the onset of cognitive dys-
function, even despite high levels of soluble Ab species
and Ab plaque load. Losartan also rescued evoked arterial,
hemodynamic and neurometabolic responses even at an
advanced pathological stage. Also, selective downregula-
tion of AT1 and restoration of AT4 receptor levels were
observed [117]. In hypertensive rats, olmesartan treatment
restored the cognitive decline and ameliorated leakage
from brain microvessels. Olmesartan also decreased brain
ATII levels [118].
Telmisartan seems to protect against hypertension-as-
sociated cognitive decline not only by its AT1 receptor
blockade, but also partly because of its PPAR-c activation
in the hippocampus. Co-administration of a PPAR-c
antagonist with telmisartan partially attenuated the pro-
tective effect of telmisartan on cognitive decline [119].
Telmisartan was also shown to significantly restore cog-
nitive functions impaired by chronic stress and decrease
forgetfulness [120].
In humans, ARBs have been shown to be associated
with a significant reduction in the incidence and progres-
sion of AD as well as dementia compared with ACEIs or
other CV drugs in a robust prospective cohort study. Dose
response effects were studied and could be observed on
candesartan, irbesartan, losartan and valsartan, with higher
doses associated with lower rates of incident dementia
[116].
The OSCAR study, evaluating the effect of 6 months of
eprosartan therapy on cognitive function resulted in sig-
nificant improvement on the overall mean Mini-Mental
State Examination (MMSE) in patients with essential
hypertension [121].
In another study, lack of significant cognitive decline
was observed with telmisartan in patients with probable
AD after 6 months of treatment, while patients treated with
amlodipine showed a worsening on the AD Assessment
Scale-Cognitive Subscale score. Regional cerebral blood
flow detected on single-photon emission computed
tomography (SPECT) was also improved in several cere-
bral regions with telmisartan use [122].
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The ongoing SARTAN-AD study, sponsored by the
Alzheimer’s Drug Discovery Foundation Canada, will
evaluate the amount of brain atrophy after telmisartan
treatment versus perindopril in patients with probable AD
and mild to moderate hypertension [123].
9 Conclusions
With an aim to prevent CV events, primarily telmisartan
and eventually losartan are the ARBs of choice in patients
with high CV risk and a general need for CV risk reduction.
In the case of HF patients, losartan, candesartan or val-
sartan should be chosen. Valsartan should also be consid-
ered for patients with left ventricular dysfunction following
a recent MI. For hypertensive patients at a higher risk of
stroke, losartan should be the first therapeutic option;
telmisartan, eprosartan and candesartan have also shown
risk reduction in this subpopulation. In the case of patients
with a history of AF, the use of telmisartan can be rec-
ommended; losartan, candesartan and valsartan have
shown a reduced incidence of new-onset AF; therefore
their use may also be beneficial in patients at risk of AF.
In patients at risk of developing DM, many ARBs (such
as losartan, telmisartan, irbesartan, candesartan and val-
sartan) have shown protective properties. Telmisartan has
also improved several indicators in those with increased IR
or DM (e.g., fasting plasma glucose and insulin levels);
therefore its use can definitely be recommended in diabetic
patients. In terms of cardioprotection in patients with DM,
both telmisartan and valsartan have shown lower risk of
admission to hospital due to MI, stroke or HF.
Based on the results of robust, well-designed trials,
losartan and irbesartan have been indicated for the treatment
of diabetic nephropathy and should be the ARBs of choice in
these patients. Valsartan and candesartan have also shown
some benefits in this population. According to a recent meta-
analysis, telmisartan may even be more beneficial in reduc-
ing proteinuria than other ARBs. Given the wide range of
available ARBs, olmesartan use should be avoided in DM
patients, especially in those with CKD, as some data suggest
increased CV risk with its use in this population.
Due to its insulin-sensitizing properties, the choice of
the PPAR-c agonist telmisartan should be considered in
obese hypertensive patients showing signs of metabolic
syndrome. Valsartan was also shown to improve insulin
sensitivity in obese hypertensive patients.
In patients with higher uric acid levels, the ARB of
choice should be losartan. Irbesartan may also have a
protective effect at therapeutic doses. Telmisartan is a
neutral agent regarding uric acid excretion, while can-
desartan, olmesartan and valsartan may increase the risk of
hyperuricemia.
The most investigated ARBs in patients with ED are
valsartan, irbesartan and losartan; the latter two have also
been studied in coexisting metabolic syndrome and DM.
Irbesartan also showed beneficial effects in patients with
ED after prostatectomy. Telmisartan did not show any
influence on ED.
Several ARBs have shown a beneficial effect on cog-
nitive function in animal studies; in human trials, ARBs
reduced the incidence as well as progression of AD and
dementia. Further research is needed in order to establish
their role in the treatment of diseases causing cognitive
impairment. Meanwhile, their use may be beneficial and
can be recommended in hypertensive patients at risk of
dementia.
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